Intestinal Research

Hye Kyung Jung

3 Articles

A Double-Blind, Randomized, Active Drug Comparative, Parallel-Group, Multi-Center Clinical Study to Evaluate the Safety and Efficacy of Probiotics (Bacillus licheniformis, Zhengchangsheng® capsule) in Patients with Diarrhea: Jun Heo, Sung Kook Kim, Kyung Sik Park, Hye Kyung Jung, Joong Goo Kwon, Byung Ik Jang; Intest Res 2014;12(3):236-244. Published online July 25, 2014; DOI: https://doi.org/10.5217/ir.2014.12.3.236

<b>Background/Aims</b><br/>

Bacillus Licheniformis, a probiotic used in the treatment of diarrhea, has been shown to suppress the growth of pathologic bacteria. This study was performed to assess the therapeutic efficacy and safety of Zhengchangsheng® (Bacillus Licheniformis) in comparison with another probiotic, Bioflor® (Saccharomyces Boulardii) for the treatment of diarrhea.

Methods

Patients with diarrhea (n=158) were randomized to receive Zhengchangsheng® or Bioflor® for 5 days. The existence or non-existence of formed feces, changes in daily stool frequency, improvement of subjective symptoms, and changes in the severity of diarrhea were compared.

Results

Of the 158 full analysis set (FAS) patient population, 151 patients comprised the per protocol (PP) analysis. The rates of recovered to formed feces in the Bacillus and Saccharomyces groups were 91.0% vs. 95.0% in the FAS (P=0.326) and 90.5% vs. 96.1% in the PP analysis (P=0.169), respectively. The mean duration of diarrhea changing to formed feces was 3.15±1.10 days in the Bacillus group and 3.22±1.01 in the Saccharomyces group (P=0.695, FAS). The frequency of defecation, subjective symptoms, and degree of severe diarrhea were improved in both groups, however, there were no statistically significant differences between the 2 groups. Analysis of the 95% confidence intervals for the differences in the rate of recovery to formed feces between the 2 groups met the criteria for non-inferiority of Bacillus compared to Saccharomyces. No significant adverse events were observed during the study period.

Conclusions

Zhengchangsheng® is not inferior to Bioflor® in therapeutic efficacy and is a safe and useful therapeutic agent for the treatment of diarrhea.

Citations

Citations to this article as recorded by

Prophylactic administration of overproducing-abscisic acid Bacillus licheniformis attenuated DSS-induced colitis in mice by regulating the gut microbiota and immune activity
Zeyan Xu, Lijiang Zhao, Mengting Wu, Anqi Cui, Wei Chen, Guohao Zheng, Jingyi Zhou, Daqing Gao, Ruihua Shi
BMC Microbiology.2025;[Epub] CrossRef
Common protein networks for various drug regimens of major depression are associated with complement and immunity
Seungyeon Lee, Sora Mun, Jiyeong Lee, Hee-Gyoo Kang
Journal of Psychopharmacology.2024; 38(9): 798. CrossRef
Baseline gut microbiome impacts probiotics Bacillus licheniformis CMCC63516 in modulating the gut microbiome and preventing antibiotic‐associated diarrhea: A double‐blind, randomized controlled trial
Qian Zhou, Wenkui Dai, Yanmin Bao, Jing Chen, Xiaohua Han, Changshan Liu, Meijie Hou, Huisheng Yao, Changsuo Hao, Shuaicheng Li, Yuejie Zheng
Clinical and Translational Medicine.2023;[Epub] CrossRef
Weizmannia coagulans: an Ideal Probiotic for Gut Health
Shiqi Zhang, Pinglan Li, Suwon Lee, Yu Wang, Chunming Tan, Nan Shang
Food Science and Human Wellness.2023; : 1. CrossRef
Bacillus licheniformis prevents and reduces anxiety-like and depression-like behaviours
Siyuan Feng, Chen Meng, Yiyuan Liu, Yue Yi, Axin Liang, Yingyu Zhang, Zikai Hao
Applied Microbiology and Biotechnology.2023; 107(13): 4355. CrossRef
Bacteremia caused by accidental injection of Bacillus licheniformis microbiota modulator through the central venous catheter
Chuan Zhong, Fen Wang, Haining Zhou, Jiarui Liu, Jiewei Hu, Yongjun Chen
Medicine.2022; 101(4): e28719. CrossRef
Bacillus licheniformis Reshapes the Gut Microbiota to Alleviate the Subhealth
Siyuan Feng, Chen Meng, Zikai Hao, Hong Liu
Nutrients.2022; 14(8): 1642. CrossRef
The effect of multispecies probiotics on cognitive reactivity to sad mood in patients with Crohn’s disease
Lipei Wu, Fujun Shen, Weiwei Wang, Chunrun Qi, Chunbin Wang, Anquan Shang, Shihai Xuan
Journal of Functional Foods.2021; 82: 104431. CrossRef
Bacillus licheniformis Zhengchangsheng® Inhibits Obesity by Regulating the AMP-Activated Protein Kinase Signaling Pathway
Xiaojie Lu, Yue Jing, Xiaofei Zhou, Naisheng Zhang, Jiandong Tai, Yongguo Cao
Probiotics and Antimicrobial Proteins.2021; 13(6): 1658. CrossRef
Oral Supplements of Combined Bacillus licheniformis Zhengchangsheng® and Xylooligosaccharides Improve High‐Fat Diet‐Induced Obesity and Modulate the Gut Microbiota in Rats
Yuyuan Li, Man Liu, He Liu, Xiaoqing Wei, Xianying Su, Ming Li, Jieli Yuan, Zongbao K. Zhao
BioMed Research International.2020;[Epub] CrossRef
Bacillus licheniformis Zhengchangsheng® attenuates DSS-induced colitis and modulates the gut microbiota in mice
Y. Li, M. Liu, J. Zhou, B. Hou, X. Su, Z. Liu, J. Yuan, M. Li
Beneficial Microbes.2019; 10(5): 543. CrossRef
Broad Prebiotic Potential of Non-starch Polysaccharides from Oats (Avena sativa L.): an in vitro Study
VANDA SARGAUTIENE, ILVA NAKURTE, VIZMA NIKOLAJEVA
Polish Journal of Microbiology.2018; 67(3): 307. CrossRef
Effect of Bacillus subtilis C-3102 on loose stools in healthy volunteers
M. Hatanaka, K. Yamamoto, N. Suzuki, S. Iio, T. Takara, H. Morita, T. Takimoto, T. Nakamura
Beneficial Microbes.2018; 9(3): 357. CrossRef
Rapid and simple detection of endospore counts in probiotic Bacillus cultures using dipicolinic acid (DPA) as a marker
Xiao-Sheng Liang, Chun Liu, Zhu Long, Xiao-Hua Guo
AMB Express.2018;[Epub] CrossRef
Gut Microbiota in Health and Probiotics in Functional Bowel Disease
Jai Hyun Rhyou
The Ewha Medical Journal.2017; 40(1): 22. CrossRef
Separation and determination of peptide metabolite of Bacillus licheniformis in a microbial fuel cell by high-speed capillary micellar electrokinetic chromatography
Wei Wang, Ruiguang Bai, Xiaoyu Cai, Ping Lin, Lihong Ma
Journal of Separation Science.2017; 40(22): 4446. CrossRef
Evaluation of chitosan hydrochloride-alginate as enteric micro-probiotic-carrier with dual protective barriers
Qing-Xi Wu, Xin Xu, Qiu Xie, Wang-Yu Tong, Yan Chen
International Journal of Biological Macromolecules.2016; 93: 665. CrossRef

11,150 View
73 Download
18 Web of Science
17 Crossref

Expression of Matrix Metallopreoteinases and Tissue Inhibitors of Metalloproteinases in Ulcerative Colitis: Seong-Eun Kim, Sung-Ae Jung, Ki-Nam Shim, Hye Kyung Jung, Tae Hun Kim, Kwon Yoo; Intest Res 2009;7(1):32-40. Published online June 30, 2009

Abstract PDF: Background/Aims
Ulcerative colitis (UC) is characterized by chronic non-specific inflammation in the mucosa and submucosa of the colon. Degradation of the extracellular matrix (ECM) is one of the major events during this process. Matrix metalloproteinases (MMPs) are important enzymes involved in the degradation of the ECM, and the activities of MMPs are controlled by its natural inhibitor, tissue inhibitor of metalloproteinases (TIMPs). This study was performed to determine the expression of MMPs and TIMPs in patients with UC. Methods: Twenty-nine patients with UC and 5 controls were included. Colonoscopic biopsies were obtained from the cecum, ascending colon, transverse colon, sigmoid colon, and rectum in each patient. The mRNA levels of expression of MMP-2 and -9, and TIMP-1 and -2 were measured separately using reverse transcription polymerase chain reactions in the mucosal specimens from each 5 segments of the colon. Results: The mRNA expression of MMP-2 and -9, and TIMP-1 in the inflamed tissues of patients with UC was significantly increased compared to non-inflamed tissues of patients with UC and controls (p＜0.05). The mRNA expression of MMP-9 and TIMP-1 in non-inflamed tissues of patients with UC was significantly higher than that of controls (p＜0.05). In inflamed tissues of UC, the mRNA expression of MMP-2 was significantly correlated with TIMP-2, and the mRNA expression of MMP-9 was significantly correlated with TIMP-1. The MMP-2/TIMP-2 ratio was increased in inflamed tissues compared to non-inflamed tissues of patients with UC and controls (p＜0.05). Conclusions: MMP-2 and-9, and TIMP-1 are likely to contribute to the inflammatory cascade in UC. MMP-2 and-9, and TIMP-1 might be important clues to solve the pathogenesis of UC. (Intest Res 2009;7:32-40)

1,681 View
16 Download

A Case of Successful Endoscopic Clipping in Iatrogenic Rectal Perforation during Colonoscopy: Ji Hyun Song, Ki Nam Shim, Seong Eun Kim, Hyun Joo Song, Hee Jung Oh, Kum Hei Ryu, Hye Jung Yeom, Tae Hun Kim, Hye Kyung Jung, Sung Ae Jung, Kwon Yoo, Il Hwan Moon; Intest Res 2005;3(2):154-155. Published online December 30, 2005

Abstract PDF: Colonoscopy has become the principal method for diagnosis, treatment, and follow-up of colorectal disease. However, colonoscopy is an invasive procedure with an associated risk of complications. Especially, perforation of the colon and rectum during colonoscopy is a rare but serious complication. The choice of conservative versus surgical treatment for this complication remains controversial. In general, conservative treatment is reserved for patient in good general health with good bowel preparation and absence of signs of peritonitis during 24 to 48 hours following the perforation. Conservative management consists of intestinal rest, intravenous fluids and antibiotics, nasogastric tube decompression, and frequent clinical examination. In case of iatrogenic perforation, if the wound is immediately closed with clips, contamination of the peritoneal cavity can be minimized. We report here a patient who sustained iatrogenic rectal perforation caused by diagnostic colonoscopy that was successfully treated by endoscopic clipping therapy. (Intestinal Research 2005;3:154-156)

1,561 View
19 Download

Author index